In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 306-314

  Cummins, Carolyn L ^a   Salphati, Laurent ^a   Reid, Michael J ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMIDAZOLAM; CYSTEINE PROTEINASE INHIBITOR; CYTOCHROME P450 3A; ELACRIDAR; FLURAZEPAM; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; INDINAVIR; K 02; KETOCONAZOLE; MIDAZOLAM; MORPHOLINE DERIVATIVE; MORPHOLINEUREAPHENYLALANYLHOMOCYSTEINYLPHENYLALANYLVINYLSULFONEPHENYLALANIN AMIDE; TRAMAZOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CONTROLLED STUDY; DISEASE MODEL; DRUG ABSORPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; ENZYME METABOLISM; ENZYME REGULATION; ENZYME SUBSTRATE; GLYCOPROTEIN SYNTHESIS; HYPOTHESIS; INTESTINE PERFUSION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATHEMATICAL COMPUTING; MESENTERIC VEIN; MESENTERY BLOOD FLOW; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE DIAGNOSIS; RAT; SINGLE PASS INTESTINE PERFUSION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DIPEPTIDES; DRUG STABILITY; INTESTINAL ABSORPTION; INTESTINES; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; OLIGOPEPTIDES; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 0037382316     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.044719     Document Type: Article

References (26)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Benet LZ, Wu CY, Hebert MF, and Wacher VJ (1996) Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release 39:139-143.
3. Chung SM, Park EJ, Swanson SM, Wu TC, and Chiou WL (2001) Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model. Pharm Res 18:544-547.
4. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
5. Dackson K, Stone JA, Palin KJ, and Charman WN (1992) Evaluation of the mass balance assumption with respect to the two-resistance model of intestinal absorption by using in situ single-pass intestinal perfusion of theophylline in rats. J Pharm Sci 81:321-325.
6. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
7. Debri K, Boobis AR, Davies DS, and Edwards RJ (1995) Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 50:2047-2056.
8. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
9. Hochman JH, Chiba M, Nishime J, Yamazaki M, and Lin JH (2000) Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:310-318.
10. Jacobsen W, Christians U, and Benet LZ (2000) In vitro evaluation of the disposition of novel cysteine protease inhibitor. Drug Metab Dispos 28:1343-1351.
11. Johnson BM, Charman WN, and Porter CJ (2001) The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism ofverapamil. J Pharm Pharmacol 53:1611-1619.
12. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
13. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
14. Li LY, Amidon GL, Kim JS, Heimbach T, Kesisoglou F, Topliss JT, and Fleisher D (2002) Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther 301:586-593.
15. Lin JH, Chiba M, Chen IW, Nishime JA, deLuna FA, Yamazaki M, and Lin YJ (1999) Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction. Drug Metab Dispos 27:1187-1193.
16. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. JPharmacol Exp Ther 283:1552-1562.
17. Salphati L and Benet LZ (1998) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
18. Salphati L, Childers K, Pan L, Tsutsui K, and Takahashi L (2001) Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol 53:1007-1013.
19. Singhal D, Ho NF, and Anderson BD (1998) Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2′, 3′-dideoxyinosine in the mesenteric vein cannulated rat ileum. J Pharm Sci 87:569-577.
20. Sutton SC, Rinaldi MT, McCarthy JM, and Vukovinsky KE (2002) A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J Pharm Sci 91:1046-1053.
21. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
22. Wacher VJ, Salphati L, and Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102.
23. Wacher VJ, Silverman JA, Zhang Y, and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
24. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
25. Wallstab A, Koester M, Bohme M, and Keppler D (1999) Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918. Br J Cancer 79:1053-1060.
26. Zhang Y, Hsieh Y, Izumi T, Lin ET, and Benet LZ (1998) Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J Pharmacol Exp Ther 287:246-252.